Table 2 A Multivariate analysis of OS according to previous given 2GTKI and B multivariate analysis of RFS according to previous given 2GTKI.

From: Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT

 

HR

95% CI

P value

A

TKI: nilotinib vs dasatinib

1.16

0.70, 1.91

0.567

TKI: seq/other vs dasatinib

1.30

0.88, 1.90

0.186

Status at allo-HCT: CP1 vs no CP1

0.70

0.48, 1.03

0.068

Karnofsky PS: <90 vs 90 or 100

1.90

1.32, 2.75

0.001

B

TKI: nilotinib vs dasatinib

0.99

0.58, 1.70

0.976

TKI: seq/other vs dasatinib

1.28

0.85, 1.92

0.244

Status at allo-HCT: CP1 vs no CP1

0.64

0.41, 1.02

0.062

Status at 2GTKI: CP1 vs no CP1

0.66

0.42, 1.05

0.078

Karnofsky PS: <90 vs 90 or 100

2.23

1.51, 3.29

<0.001

Back to article page